US action date for Acorda's fampridine pushed back to January
This article was originally published in Scrip
Executive Summary
The US FDA has extended by three months the user fee date for Acorda Therapeutics' multiple sclerosis agent fampridine sustained-release (proposed trade name Apriva) following the company's recent submission related to a risk evaluation and mitigation strategy (REMS). The new user fee date is January 22nd.